Congress mandates healthcare price disclosure—but will patients actually use it?

What it does

This bill requires hospitals, insurers, clinical laboratories, imaging centers, and ambulatory surgical centers to publicly disclose their standard prices for medical services in machine-readable and consumer-friendly formats, updated quarterly. It mandates disclosure of gross charges, discounted cash prices, payer-specific negotiated rates, and ownership information, with civil penalties up to $35 per bed per day for non-compliance and restrictions on debt collection during non-compliance periods.

Why we flagged it

The bill's core mechanism is a regulatory requirement forcing disclosure of pricing data across multiple healthcare sectors. It is fundamentally a transparency and accountability measure, not a subsidy, carve-out, or deregulation.

What the text implies

• Disclosure of payer-specific negotiated rates may reveal competitive pricing strategies and enable reverse-engineering of negotiation leverage, potentially affecting future contract negotiations between insurers and providers.
• The bill requires disclosure of ownership and management relationships but defers to HHS rulemaking to define scope; vague ownership thresholds could create compliance uncertainty and selective disclosure.
• Quarterly updates create a moving target for compliance; providers must continuously monitor and re-disclose, increasing operational burden and potential for inadvertent non-compliance triggering penalties.
• De-identified maximum and minimum negotiated charges may still allow sophisticated actors to infer individual payer rates through statistical analysis, undermining confidentiality protections.
• The bill does not address how patients will actually USE disclosed prices (e.g., no requirement for patient education, no integration with insurance benefits tools), limiting practical utility.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary patients gain direct access to pricing information that was previously opaque, enabling price comparison and informed decision-making before receiving care. The bill restricts providers' ability to pursue aggressive debt collection during periods of non-compliance, protecting vulnerable patients. However, the benefit depends on effective implementation and whether disclosed prices are sufficiently granular to be actionable.

Who stands to gain

• health information technology vendors (price transparency software/platforms)
• patient advocacy organizations (data access for comparative analysis)
• price comparison and healthcare shopping platforms

Named in the bill

HHS Secretary, Centers for Medicare & Medicaid Services (CMS), Hospitals, Health insurance issuers, Clinical diagnostic laboratories, Imaging service providers, Ambulatory surgical centers, Third-party payers, Johnson & Johnson (JNJ), Bristol Myers Squibb (BMY), American International Group (AIG), Farfetch Limited (FBK) — and 1 more

Where it stands

25 cosponsors: 14 Democrats, 11 Republicans.

• Jul 17, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 17, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
• Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”
• Jul 22, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

69 lobbying clients named this bill on 82 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $34,395,567 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 99% of bills with at least one filing.

Roger Marshall, the sponsor, reported $1,777,391 in PAC receipts in the 2026 cycle. $21,500 of that came from 3 PACs tied to these lobbying clients.

• American Hospital Association — $4,470,000 on 1 filing
• Elevance Health, Inc. — $4,010,000 on 2 filings
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Boeing Company — $2,770,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.